18PAnti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer
ConclusionsDIF-1 exerts anti-cancer effects in TNBC by reducing cell cycle accelerators and reversing EMT. Our findings suggest that using DIF-1 as a lead compound could develop a novel anti-cancer agent for TNBC.Legal entity responsible for the studyThe study protocol was approved by the Committee on Ethics of Animal Experiments of Kyushu University. Animal handling and procedures were carried out in compliance with the Guidelines for Animal Experiments, Kyushu University, and the Law (No. 105) and Notification (No. 6) of the Japanese Government.FundingHas not received any funding.DisclosureAll authors have declared no co...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1146PImpact of tumour site and adjuvant radiotherapy on survival in adenoid cystic carcinoma: A SEER database analysis
ConclusionsThese results, based on SEER data, suggest that aRT is associated with favorable survival only in late-stage ACC and that, among these late-stage tumors, submandibular gland ACCs have substantially worse prognosis than other sites, irrespective of aRT.Legal entity responsible for the studyThe authors.FundingAcademy of Athens PhD Scholarship to Jason Tasoulas; UNC Lineberger Tier 3 Developmental Award funds and the University Cancer Research Fund to A.L. Amelio.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1593TiPPhase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody ®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
AbstractBackgroundPreclinical evidence shows that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2) promote an immunosuppressive state in the tumour microenvironment, and that the combination of anti-VEGF/Ang2 with anti-PD-1 therapy promotes an immunopermissive state supportive of T-cell mediated tumour cell killing. BI 836880, a humanised bispecific nanobody that targets VEGF and Ang2, and BI 754091, an anti-PD-1 antibody, have shown safety and preliminary antitumour activity as monotherapies in phase I studies (RP2D, 720 mg iv q3w for BI 836880 and 240 mg iv q3w for BI 754091). The safety and effic...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
473PPhase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
ConclusionsLapatinib and trametinib could be combined in an intermittent dosing schedule with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed with sufficient target engagement.Clinical trial identificationNCT02230553.Legal entity responsible for the studyThe Netherlands Cancer Institute.FundingNovartis.DisclosureN. Steeghs: Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Bristol-Meyers Squibb; Research grant / Funding (institution): Novartis; Research grant / Funding (institution):...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1147PEfficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
ConclusionsAnlotinib showed a high disease control rate in patients with RMSGCs. The toxicity was tolerable and manageable.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
254PAnti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer (BC): A prospective clinical study
ConclusionsSC significantly decreases AMH and AFC values independently of chemotherapeutic agents in patients with BC. The low AMH levels and less AFC before SC may predict CIA.Legal entity responsible for the studyİstanbul Demiroğlu Bilim University.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1594TiPRadiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial
AbstractBackgroundTumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality comprising alternating electric fields. TTFields have demonstrated efficacy in preclinical non-small cell lung cancer (NSCLC) models. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma. The METIS study [NCT02831959] investigates the efficacy and safety of TTFields in NSCLC patients with brain metastases.Trial designNSCLC patients (N = 270) with 1-10 brain metastases are randomized 1:1 to stereotactic radio surgery (SRS) followed by continuous TTFields (...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
474PPharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
ConclusionsStandard platinum-doublet chemotherapy regimens did not alter the PK of D+T or D compared with historical monotherapy therapy data. Toxicities were manageable and were not associated with PK.Clinical trial identificationNCT02537418.Legal entity responsible for the studyCanadian Cancer Trials Group (CCTG).FundingAstraZeneca provided drug and partial funding to support of this Canadian Cancer Trials Group (CCTG) study.DisclosureD. Hao: Honoraria (self), Advisory Board: Roche; Honoraria (self), Advisory Board; funding for clinical trial: BMS; Honoraria (self), Research grant / Funding (institution), Advisory Board;...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
255PPrognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
ConclusionsThe outcome of selected apocrine triple negative breast cancer patients is excellent and possibly deserves a treatment de-escalation. Multicenter projects focusing on the possibility to avoid adjuvant chemotherapy in selected subtypes of triple negative breast cancers with favorable outcome are warranted.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureG. Cancello: Honoraria (self): Pierre Fabre. E. Montagna: Honoraria (self): Pierre fabre; Honoraria (self): gentili. E. Munzone: Honoraria (institution), Advisory / Consultancy: Pierre Fabre; Honoraria (institution), ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1148PACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data
ConclusionsIn the stage 1 of the ACCURACY trial, 12 pts with Notch1-4act mut are being treated with the pan-Notch inhibitor AL101. The trial will advance to stage 2 if ≥ 2 pts respond. Efficacy/safety data on these first 12 pts will be presented at the meeting. Accrual to stage 2 is ongoing.Clinical trial identificationNCT03691207.Editorial acknowledgementFrancesca Balordi, PhD, of The Lockwood Group (Stamford, CT, USA), in accordance with Good Publication Practice (GPP3) guidelines, funded by Ayala Pharmaceuticals, Inc.Legal entity responsible for the studyAyala Pharmaceuticals, Inc.FundingAyala Pharmaceuticals, In...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
19PThe inhibitory effect in oral squamous cell carcinoma cells by knocking down matrix metalloproteinase 9
ConclusionsMMP-9 plays an important role in OSCC cells metastasis.Legal entity responsible for the studyBeijing Stomatological Hospital& School of Stomatology, Capital Medical University.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1595TiPNivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial
AbstractBackgroundTreatment landscape for patients with advanced NSCLC is rapidly evolving, with recent randomized phase III trials demonstrating superiority of chemo-immuno combinations versus chemotherapy alone. Role of chemo-free combinations, including NI, is under investigation with limited available data. Aim of the present trial is to investigate outcome of SqCLC patients when treated with NI or CN.Trial designSQUINT (NCT03823625) is an open-label, randomized, parallel, non-comparative phase II study designed to assess the efficacy of NI (Arm A) or CN (Arm B) in patients with advanced, metastatic SqCLC. Eligibility ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
475PA phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
ConclusionsThe combination of ALRN-6924 and palbociclib at pharmacologically relevant doses is feasible and generally well tolerated.Clinical trial identificationNCT02909972.Legal entity responsible for the studyAileron Therapeutics, Inc.FundingAileron Therapeutics, Inc.DisclosureF. Meric-Bernstam: Honoraria (self): Sumitomo Dainippon Pharma; Dialectica; Advisory / Consultancy: Genentech; Advisory / Consultancy: Inflection Biosciences; Advisory / Consultancy: Pieris; Advisory / Consultancy: Darwin Health; Advisory / Consultancy: Samsung bioepis; Advisory / Consultancy: Aduro; Advisory / Consultancy: Spectrum; Advisory / Co...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
256PNovel blood based circulating tumour cell biomarker for breast cancer detection
ConclusionsIn this initial study, CTC was a significant predictor of cancer. The CTC assay can easily be combined with cfDNA to enhance detection rates. Proof-of-concept data suggests potential for a rule out test to avoid unnecessary follow-up/biopsies in BIRADS 3/4 patients.Legal entity responsible for the studyCellMax Life.FundingCellMax Life.DisclosureF. Lin: Shareholder / Stockholder / Stock options: CellMax Life. J. Wu: Shareholder / Stockholder / Stock options: CellMax Life. H.B. Hsieh: Shareholder / Stockholder / Stock options: CellMax Life. S. Chang: Shareholder / Stockholder / Stock options: CellMax Life. M. Jave...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1149PPathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment
ConclusionsUpstaging is common in AJCC 8, and upstaged tumors demonstrate improved survival; these factors that should be kept in mind when interpreting data using the new staging system. Postoperative radiotherapy may reduce death in newly upstaged pT3N0 patients, and further study is needed in this area.Legal entity responsible for the studyYale School of Medicine.FundingResearch reported in this publication was supported by the National Institute on Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35DK104689 (NCJL). The content is solely the responsibility of the author...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
